Anti-Inflammatory Drugs Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Anti-inflammatory drugs encompass a broad class of therapeutics designed to reduce inflammation, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, anti-inflammatory biologics, and other small molecule agents. These medicines are widely prescribed for conditions ranging from osteoarthritis, rheumatoid arthritis, and musculoskeletal pain to asthma, inflammatory bowel disease, and certain cardiovascular indications. The market serves a large and growing patient base, with both prescription and over-the-counter products contributing to global revenues.

• •Global market valued at approximately USD 131.68 billion in 2025.
• •Forecast compound annual growth rate of around 5.72% annually.
• •Long-term projections place the market beyond USD 270 billion by the mid-2030s.

A primary growth driver is the rising global prevalence of chronic inflammatory diseases, including arthritis, autoimmune disorders, and inflammatory bowel disease, which collectively affect hundreds of millions of people worldwide. Aging populations in both developed and emerging economies are expanding the patient pool, while greater physician awareness and improved diagnostic capabilities are increasing treatment rates. Additional momentum comes from the launch of advanced biologics, monoclonal antibodies, and Janus kinase (JAK) inhibitors, which offer targeted mechanisms of action and improved outcomes for patients who do not respond to traditional therapies.

• •Rising incidence of arthritis, autoimmune diseases, and chronic pain conditions.
• •Aging populations in North America, Europe, and Asia-Pacific boosting demand.
• •Innovation in biologics, biosimilars, and targeted small-molecule therapies.

The market is commonly segmented by drug class, including anti-inflammatory biologics, corticosteroids, NSAIDs, and other agents, with biologics representing the fastest-growing category due to their premium pricing and expanding indications. By indication, the largest segments include arthritis, respiratory diseases, and gastrointestinal disorders, while by route of administration, oral formulations lead but injectable biologics are growing rapidly. Geographically, North America accounts for the largest share of revenue, followed by Europe, with Asia-Pacific identified as the fastest-growing region on the back of improving healthcare access and rising disposable income.

• •Biologics are the fastest-growing drug class; NSAIDs and corticosteroids remain high-volume categories.
• •North America holds the largest revenue share; Asia-Pacific is the fastest-growing region.
• •Hospital pharmacies, retail pharmacies, and online channels are the main distribution pathways.

What are the recent trends and outlook?

Key trends shaping the market include the shift toward precision medicine and personalized anti-inflammatory therapies, increased investment in oral small-molecule alternatives to injectable biologics, and the rapid uptake of biosimilars as patents on blockbuster biologics expire. Digital health tools and real-world evidence are also being used to refine treatment pathways and demonstrate value to payers. Looking ahead, the market is expected to maintain steady mid-single-digit growth, supported by pipeline innovation, expanding indications, and rising healthcare access in emerging markets.

• •Pipeline focus on JAK inhibitors, IL inhibitors, and oral anti-inflammatory alternatives to injectables.
• •Biosimilar competition is intensifying in established biologic categories.
• •Long-term outlook points to continued mid-single-digit growth, with biologics driving incremental value.